All studies
Oncology · Registry · England

Chesanga 2025

Prostate cancer

PPSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
1
2 treatments

Comparisons

1 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Seven-year all-cause mortality
vs PR07·HR·Efficacy
0.770.61–0.98
0.580.51–0.65
not pooledClose alignment

Design and methods

Estimand
PP
Design hypothesis
Superiority
Matching / weighting
Clone-censor-weight
Analysis method
Landmark clone-censor-weight analysis with bootstrap
Missing data
Complete case
DAG
No
QBA
No

Data and sample

Data type
Registry
Data sources
4
Geography
England
Eligible sample
2690
Treated
2201
Control
489
Emulations
1
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
AstraZeneca and other disclosed relationships
Funding
Declared: Public, Private
Funders
ESRC; AstraZeneca PhD studentship; UKRI; HQIP; NHS England; Welsh Government

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2025_Chesanga_ProstateCancer
DOI
10.1016/j.jclinepi.2025.111767
Affiliations
London School of Hygiene and Tropical Medicine; Royal College of Surgeons of England; AstraZeneca
Sector
Academia, Industry
Target trials (study level)
PR07
Registration
NCT00002633